Fujirebio Diagnostics AB of Gothenburg at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair

Fujirebio Diagnostics AB

P.O. Box 121 32, 402 42 Gothenburg
Elof Lindälvsgata 13, 414 58 Gothenburg

Telephone +46 31 857030
Fax +46 31 857040

Hall map

MEDICA 2017 hall map (Hall 3): stand B42

Fairground map

MEDICA 2017 fairground map: Hall 3

Our range of products

Our products

Product category: Tumor markers


A serological marker correlated with cccDNA for improved monitoring of HBV patients under treatment
The most common used treatment for patients with chronic HBV infection are nucleos(t)ide analogues (NUC’s). This treatment has overcome the problem of side-efects and genotype-dependency that is observed in the treatment with pegylated-interferon. However, where treatment with interferon is finite, this is not the case with NUC´s.

Potential stopping rules for treatment are therefore highly wanted by both the clinicians and the patients. Another difficulty is that the active replication of HBV can only be determined by an invasive and non-standardized way: measurement of covalently closed circular DNA (cccDNA) which is very dependent on the technology used and this from a liver biopsy which is an invasive sample to collect.

Patients today are monitored with diferent tools such as ALT, HBV DNA and (quantifcation of) hepatitis B surface antigen. HBcrAg can serve to measure the replication of the virus and is today already used in Japan in routine monitoring to identify patients where treatment can be discontinued.1


Ohishi W, et al. Treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol. Res. 2012 Mar; 42(3): 219-25.

More Less

Product category: Tumor markers


An add-on marker for the diagnostic and management of Interstital Lung Diseases (ILDs)
Krebs von den Lungen 6 (KL-6) is a mucin-like, highmolecular weight glycoprotein expressed on the surface membrane of alveolar epithelial cells (AEC-II) and bronchiolar epithelial cells. It exists as solubilized component in the pulmonary epithelial lining fluid by proteolytic cleavage.

  • When these cells are proliferating, stimulated or injured, KL-6 is released into the blood vessel (damaged barrier).
  • KL-6 has chemotactic, proliferative effects on fibroblasts. It correlates with fibrogenesis.
  • KL-6 is a good marker of AEC injury. Its role in patients with Interstital Lung Diseases (ILDs) and connective tissue diseases has been extensively studied 1.

Ishikawa et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. RESPIRATORY INVESTIGATION 2012; 50:3–13

More Less

Product category: Tumor markers


Mesothelin - The novel, non-invasive in vitro biomarker to aid in the diagnosis of Mesothelioma
Mesothelioma is a rare form of cancer that is linked to exposure to asbestos. Although malignant mesothelioma remains a relatively uncommon malignancy, it continues to represent an important cause of mortality in numerous areas worldwide; eg, England, Wales, continental Europe, and Australia. Recent estimates suggest that in coming decades, as much as 1% of deaths among men in the United Kingdom currently aged 49-54 may be due to mesothelioma.1 Age standardized incidence rates for mesothelioma in men range from around 8 per 100,000 in Scotland, England, and The Netherlands; 2-4 per 100,000 in France, Italy, and Germany; and 1 per 100,000 in Spain.2 The corresponding rate for Australia is estimated to be around 6 per 100,000.3 The disease is more likely to occur in men than in women.

There are 3 classifications of mesothelioma:

Pleural — cancer in the chest cavity.

Peritoneal — cancer that starts in the abdomen. (This classification is a form that represents between 10-20% of the mesotheliomas diagnosed.)

Pericardial — cancer in the cavity around the heart. (The most rare form of mesothelioma.)

More Less

Product category: Tumor markers


Piecing together the risk factors for stomach cancer
Pepsinogen is a precursor of pepsin, a protease secreted in stomach, and is immunologically categorized into two main classes, pepsinogenⅠand pepsinogen Ⅱ. PepsinogenⅠ exists in fundic gland mucosa, while pepsinogenⅡ exists more broadly, in organs including fundic gland mucosa, cardiac glandpyloric gland, duodenal gland.1 Pepsinogen I value and pepsinogenⅠ/ pepsinogenⅡ ratio both correlate with extent of the fundic gland area expansion, and it is useful as a marker of chronic atrophic gastritis progression. Atrophic gastritis progressions is strongly related with stomach cancer,2 and those with severe atrophic change have higher frequency of cancer being found. 3-4 

Sanloff IM, et al. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal histology. Gastroenterology, 83: 204-209, 1982.
Correa P. The gastric precancerous process. Cancer Survey, 2: 438-450, 1983.
Miki K. Gastric Cancer Screening Using Serum Tests (Stomach Dry Dock) -Study of the Systems of the First Screening for Cancer-susceptible Subjects by Serum Pepsinogen Levels and the Secondary Close-examination by Every-Other-Year Panendoscopy. Nippon Shokaki shudankenshin gakkaishi, 84: 141-144, 1989.
Nishizawa M. An outlook of gastric mass screening (1st report). Nippon Shokaki shudankenshin gakkaishi, 84: 141-144, 1989.

More Less

Product category: Tumor markers


Biomarkers for Alzheimer's disease

Alzheimer’s disease (AD) is the most common form of dementia and is histologically characterized by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout the brain.

The major constituents of amyloid plaques are the β-amyloid peptides consisting of 40 and 42 amino acids, which are derived from the amyloid precursor protein.

Neurofibrillary tangles are made up of paired helical filaments consisting of hyperphosphorylated tau protein (phospho-tau). Tau protein, present in the brain in 6 different isoforms, is an intracellular protein that is released upon neuronal death.

The INNOTEST® assays from Fujirebio are solid-phase enzyme immunoassays for the quantitative determination of β-amyloid(1-42), β-amyloid(1-40), total tau, and phospho-tau(181P) in human cerebrospinal fluid. The combined use of these markers allows identification of AD pathology ante-mortem.

These markers can be used in clinical routine to discriminate AD from normal aging1, other neurological diseases and other types of dementia (non-AD). Interpretation of the results, however, should always be done in combination with other clinical information.



More Less

About us

Company details

More than 50 years' experience in pioneering IVD testing solutions 

We are a global leader in the field of high quality in vitro diagnostics (IVD) testing. At Fujirebio (our name is pronounced Fuji-Ray-Bee-o and symbolizes restoration of health) we have more than 50 years’ accumulated experience in the discovery, development, manufacturing and worldwide commercialization of robust IVD products.

Historically based in Japan with the country’s deeply rooted culture of excellence Fujirebio has over the years been shaped by the successful integration of pioneering and experienced international IVD players such as Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Our global presence includes offices in the United States, Europe, Latin America and Asia as well as a vast international distribution network.

More Less